Novartis' newly approved heart failure therapy Entresto could set precedents by bringing outcome-based pricing for a primary care drug to the United States.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
PowerPoint slides
Rights and permissions
About this article
Cite this article
Senior, M. Heart drug pushes outcome-based pricing plans. Nat Rev Drug Discov 14, 665–667 (2015). https://doi.org/10.1038/nrd4741
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd4741